Check-Cap Ltd. (CHEK)

Market Cap	10.41M
Revenue (ttm)	n/a
Net Income (ttm)	-17.72M
Shares Out	5.85M
EPS (ttm)	-3.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,000
Open	1.56
Previous Close	1.55
Day's Range	1.56 - 1.78
52-Week Range	1.22 - 9.20
Beta	0.39
Analysts	Strong Buy
Price Target	7.00 (+293.26%)
Earnings Date	May 11, 2023

About CHEK

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application tha...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Feb 19, 2015
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: CHEK

Analyst Forecast

According to one analyst, the rating for CHEK stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(293.26% upside)

Analyst Consensus: Strong Buy